the Effect of Calcium Dobesilate on Non Dialysis Patients With CKD
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03427944 |
|
Recruitment Status : Unknown
Verified January 2018 by The Affiliated Hospital of Xuzhou Medical University.
Recruitment status was: Recruiting
First Posted : February 9, 2018
Last Update Posted : February 14, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Chronic Renal Failure | Drug: Calcium Dobesilate group Drug: Conventional Treatment group | Phase 4 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 100 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | the Effect of Calcium Dobesilate on Non Dialysis Patients With Chronic Renal Failure |
| Actual Study Start Date : | January 2015 |
| Estimated Primary Completion Date : | December 31, 2018 |
| Estimated Study Completion Date : | December 31, 2018 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Calcium Dobesilate group
Calcium dobesilate group was treated with calcium dobesilate (500mg, tid , po), its conservative treatment was the same as that of the conventional treatment group
|
Drug: Calcium Dobesilate group
Calcium dobesilate was used to treat patients with chronic renal failure on the basis of conventional treatment.
Other Name: Treatment group |
|
Placebo Comparator: Conventional Treatment group
conventional treatment group was treated with conventional conservative treatment of renal failure (low protein, low salt, low fat, low phosphorus diet, balance the internal environment; control blood pressure ; remove intestinal toxins etc.)
|
Drug: Conventional Treatment group
Conventional treatment were used to treat patients with chronic renal failure.
Other Name: Control group |
- glomerular filtration rate [ Time Frame: up to 6 months ]emission computed tomography
- serum creatinine [ Time Frame: up to 6 months ]intravenous blood sampling
- Cystatin C [ Time Frame: up to 6 months ]intravenous blood sampling
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Enroll the non dialysis patients with chronic renal failure hospitalized in the Department of Nephrology of the Affiliated Hospital of Xuzhou Medical University.
- According to the glomerular filtration rate, the patients who were not required to be dialysate were at CKD3-5 (GFR between 10 and 59ml/min).
Exclusion Criteria:
- Exclude those patients with diabetes, cardiovascular disease, severe infection, shock, dehydration, abnormal liver function, received glucocorticoid therapy, surgery and emergency dialysis.
- Eliminate those patients with respiratory disease(such as chronic obstructive pulmonary disease, bronchiectasis, asthma), cardiovascular diseases(such as acute and chronic cardiac insufficiency), blood system diseases (such as aplastic anemia, nutritional anemia and polycythemia vera).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03427944
| Contact: Dong Sun, MD | 15862158578 | sundong126@yahoo.com |
| China, Jiangsu | |
| The Affiliated Hospital of Xuzhou Medical University | Recruiting |
| Xuzhou, Jiangsu, China, 221000 | |
| Contact: Dong Sun, MD 15862158578 sundong126@yahoo.com | |
| Study Director: | Dong Sun, MD | The Affiliated Hospital of Xuzhou Medical University |
| Responsible Party: | The Affiliated Hospital of Xuzhou Medical University |
| ClinicalTrials.gov Identifier: | NCT03427944 |
| Other Study ID Numbers: |
XYFY2016-KL001-02 |
| First Posted: | February 9, 2018 Key Record Dates |
| Last Update Posted: | February 14, 2018 |
| Last Verified: | January 2018 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | No |
|
Calcium Dobesilate Non Dialysis Patients With CKD(3-5) Glomerular filtration rate serum creatinine |
|
Renal Insufficiency Kidney Failure, Chronic Renal Insufficiency, Chronic Kidney Diseases Urologic Diseases Calcium Dobesilate |
Calcium Calcium-Regulating Hormones and Agents Physiological Effects of Drugs Hemostatics Coagulants |

